

# Enhanced Formulations

---

CASE STUDY



[www.corerxpharma.com](http://www.corerxpharma.com)

# Enhanced Formulations



## *Solubility Enhancement*

Increase bioavailability for dose escalation study



### THE CHALLENGES

- ↻ Low bioavailability observed with existing neat API-in-Capsule.
- ↻ Severe side effects were observed with 72mg dose, so the dose was reduced to 63mg, however, a further reduction in strength was required.



### THE SOLUTION

- ↻ Produce an amorphous form of solubilized material with surfactant using hot melt granulation (high shear granulation with jacketed bowl). Fill the granules into capsules using Quantos technology.



### THE RESULTS

- ↻ Successfully achieved an increase in bioavailability. PK study showed 32mg dose was equivalent to 63mg dose.
- ↻ Currently evaluating 9mg dose in Covid study, 26mg dose in prostate cancer study, and 32mg dose in three triple negative breast cancer trials.